GENENTA SCIENCE S.P.A. - AMERICAN DEPOSITARY SHARE

Genenta Showcases Strategic Vision at Premier Biotech Forum in Qatar

15 Apr 2025 05:00:00 By Nasdaq GlobeNewswire

Genenta Announces €20 million ($21.9M) Financing To Expand Pipeline As Brain Tumor Trial Is Showing Promising Survival Rates

19 Mar 2025 09:28:00 By Nasdaq GlobeNewswire

Genenta Strengthens Agreement with AGC Biologics to Boost Cell Therapy Manufacturing

09 Jan 2025 06:00:00 By Nasdaq GlobeNewswire

Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

23 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

02 Oct 2024 06:30:00 By Nasdaq GlobeNewswire

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

06 May 2024 06:25:00 By Nasdaq GlobeNewswire

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

08 Feb 2024 05:00:00 By Nasdaq GlobeNewswire

Genenta to Present at Upcoming Scientific and Investor Conferences

06 Sep 2023 07:00:00 By Nasdaq GlobeNewswire

Genenta Announces Ongoing Clinical Trial Progress and Proposed Expansion in Solid Tumor Treatments

28 Jul 2023 03:00:00 By Nasdaq GlobeNewswire

The European Commission Grants Orphan Drug Designation to Temferon™ for Treatment of Glioma

29 Jun 2023 07:00:00 By Nasdaq GlobeNewswire

Genenta to Provide Update on Lead Product Temferon™

16 May 2023 07:00:00 By Nasdaq GlobeNewswire

Genenta Announces Fiscal Year 2022 Financial Results and Annual Report on Form 20-F Filing

26 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

Genenta Announces Extension of License Agreement with Ospedale San Raffaele to All Solid Tumor Indications

03 Apr 2023 07:00:00 By Nasdaq GlobeNewswire

FDA Grants Orphan Drug Designation to Temferon for Treatment of Glioblastoma Multiforme

02 Mar 2023 06:45:00 By Nasdaq GlobeNewswire

Genenta Science and AGC Biologics Enter Development and Manufacturing Service Agreement

07 Feb 2023 07:00:01 By Nasdaq GlobeNewswire

Genenta Update at SITC22 Indicates Potential for Anti-Tumor Immune System Reset after Temferon™ Treatment in Glioblastoma Patients

07 Nov 2022 08:05:00 By Nasdaq GlobeNewswire

Genenta Provides First Half 2022 Business Update and Financial Results

24 Oct 2022 07:30:00 By Nasdaq GlobeNewswire

Genenta to Present at Upcoming Scientific and Investor Conferences

05 Oct 2022 08:05:00 By Nasdaq GlobeNewswire

Genenta to Present at Upcoming Investor Conferences

07 Sep 2022 07:00:01 By Nasdaq GlobeNewswire

AmCham Italy and Genenta Science Announce the Bowling Green Bull Initiative

25 Jul 2022 06:00:00 By Nasdaq GlobeNewswire